氨茶碱对冠心病患者使用替格瑞洛致呼吸困难的干预研究

王小东; 周华; 张旭敏; 胡铂; 刘亚玲

doi:10.13201/j.issn.1001-1439.2017.05.008

氨茶碱对冠心病患者使用替格瑞洛致呼吸困难的干预研究

- 1. 同济大学附属东方医院心内科(上海, 200120);
- 2. 上海交通大学附属仁济医院麻醉科
基金项目:
上海市浦东新区卫计委面上项目资助（No：PW2014A-16）

详细信息

通讯作者: 刘亚玲,E-mail:liuyaling198003@126.com

中图分类号: R541.4

收稿日期: 2016-12-03

修回日期: 2017-03-15

The effect of aminophylline on ticagrelor-induced dyspnea in coronary heart disease

- 1. Department of Cardiology, Shanghai East Hospital, Tongji University, School of Medicine, Shanghai, 200120, China;
- 2. Department of Anesthesiology, Renji Hospital, Shanghai Jiaotong University, School of Medicine

More Information

Corresponding author: LIU Yaling, E-mail: liuyaling198003@126.com

Received Date: 03 December 2016

Revised Date: 15 March 2017

摘要

摘要: 目的：研究氨茶碱对冠心病患者使用替格瑞洛后出现呼吸困难的干预效果。方法：纳入使用替格瑞洛3 d时出现呼吸困难的冠心病患者181例，随机分为氨茶碱组81例（氨茶碱0.1~0.3 g/d）和对照组80例（维生素C 1.0~3.0 g/d），检测血小板反应指数（PRI），测定血清腺苷浓度（高效液相色谱法），采用主观方法（mMRC量表）和客观方法（呼吸功能）评价呼吸困难发生情况；随访1个月，观察终点事件（心血管死亡，心肌梗死，不稳定心绞痛，支架内血栓，急、慢性呼吸衰竭）发生情况。结果：替格瑞洛使用期限为（1.0±0.2）个月，氨茶碱治疗时间为（1.0±0.8）个月。两组基线水平无差异；与治疗前相比，1个月后两组PRI均有所降低（均P<0.05）；在各个时间点，PRI在两组无显著性差异；氨茶碱显著降低了血清腺苷水平；无论是主观呼吸困难mMRC评分，还是客观呼吸功能检测，氨茶碱均改善了呼吸功能，并且降低了急慢性呼吸衰竭的发生；氨茶碱未减少心血管事件。结论：对于使用替格瑞洛导致呼吸困难的冠心病患者，氨茶碱可有效减轻呼吸困难，降低呼吸衰竭的发生。
- 氨茶碱 /
- 替格瑞洛 /
- 呼吸困难
Abstract: Objective: To evaluate the effect of aminophylline on ticagrelor-induced dyspnea in coronary heart disease. Method: Patients with ticagrelor-induced dyspnea occurred 3 days after ticagrelor were recruited. They were randomized into aminophylline group (aminophylline 0.1-0.3 g/d,n=81) and control group (vitamin C 1.0-3.0 g/d, n=80). Platelet reactivity index (PRI), serum adenosine, modified dyspnea scale (mMRC), forced expiratory volume in first second (FEV1), and forced vital capacity (FVC) were measured. Clinical endpoints (cardiovascular death, myocardial infarction, UAP, stent thrombosis, acute or chronic respiratory failure) were recorded. Result: Aminophylline and vitamin C were prescribed in the whole following up period (1 month). There was no significant difference of baseline characteristics between two groups. PRI decreased after 1 month in both groups (P<0.05), but without significant difference between the two groups. Aminophylline not only decreased serum adenosine level, but also alleviate dyspena. While improving respiratory function, aminophylline decreased acute or chronic respiratory failure, without affecting major adverse cardiovascular events (MACE). Conclusion: Aminophylline alleviates dyspena and decrease respiratory failure without affecting platelet reactivity and cardiovascular events.
- aminophylline /
- ticagrelor /
- dyspnea

HTML全文

参考文献(15)

[1]	ROFFI M, PATRONO C, COLLET J P, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37:267-315.
[2]	WALLENTIN L, BECKER R C, BUDAJ A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med, 2009, 361:1045-1057.
[3]	STOREY R F, BLIDEN K P, PATIL S B, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET Study[J]. J Am Coll Cardiol, 2010, 56:185-193.
[4]	GURBEL P A, BLIDEN K P, BUTLER K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies:The RESPOND Study[J]. Circulation, 2010, 121:1188-1199.
[5]	VAN GIEZEN J J, SIDAWAY J, GLAVES P, et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model[J]. J Cardiovasc Pharmacol Ther, 2012, 17:164-172.
[6]	NISHIYAMA O, TANIGUCHI H, KONDOH Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis[J]. Eur Respir J, 2010, 36:1067-1072.
[7]	VAN GIEZEN J J, SIDAWAY J, GLAVES P, et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model[J]. J Cardiovasc Pharmacol Ther, 2012, 17:164-172.
[8]	GAUBERT M, LAINE M, RICHARD T, et al. Effect of ticagrelor-related dyspnea on compliance with therapy in acute coronary syndrome patients[J]. Int J Cardiol, 2014, 173:120-121.
[9]	BONELLO L, LAINE M, KIPSON N, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome[J]. J Am Coll Cardiol, 2014, 63:872-877.
[10]	BUTLER K, MAYA J, TENG R, et al. Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients[J]. Curr Med Res Opin, 2013, 9:569-577.
[11]	ARMSTRONG D, SUMMERS C, EWART L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1[J]. J Cardiovasc Pharmacol Ther, 2014, 19:209-219.
[12]	DINICOLANTONIO J J, TOMEK A. Misrepresentation of vital status follow-up:challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel[J]. Int J Cardiol, 2013, 169:145-146.
[13]	HEADRICK J P, LASLEY R D. Adenosine receptors and reperfusion injury of the heart[J]. Handb Exp Pharmacol, 2009, (193):189-214.
[14]	葛均波徐永建.内科学[M]. 8版. 北京:人民卫生出版社,2013:141-146.
[15]	李俊. 临床药理学[M]. 4版. 北京:人民卫生出版社,2008:334-335.